

SUB
B4
COO't
A2
COO't

16. (Amended) A method of treatment of wounds and/or tissue repair comprising administering to a patient suffering from a wound and/or tissue damage a composition comprising the delivery vehicle of Claim 8.

17. (Amended) A nucleic acid according to Claim 1 and/or a protein according to Claim 7 for use as a pharmaceutical.

18. (Amended) Use of the nucleic acid according to Claim 1 and/or the protein according to Claim 7 for the manufacture of a medicament for the treatment of orofacial clefting and/or wound healing and/or tissue repair.

A 3 SUB
B6

21. (Amended) A nucleic acid according to Claim 19 that is murine in origin.

A 4 SUB
B8

23. (Amended) A delivery vehicle comprising the isolated nucleic acid molecule according to Claim 20 and/or the polypeptide according to Claim 22.

NE

26. (Amended) Use of antibodies according to Claim 24 in diagnosing and/or detecting orofacial clefting.

NE

29. (Amended) A method of producing a transgenic mammal according to Claim 28 wherein the transgenic mammal is a mouse.

30. (Amended) A method of producing the transgenic mammal according to Claim 27 wherein the gene encoding the tissue repair protein is the nucleic acid molecule comprising a nucleotide sequence which hybridizes to the nucleic acid of SEQ ID NO: 3 under high stringency conditions.

NE

32. (Amended) A method of producing a transgenic mammal according to Claim 27 wherein the gene encoding the tissue repair protein is a nucleic acid molecule which encodes a tissue repair protein and comprises a nucleotide sequence which hybridizes to the nucleic acid of SEQ ID NO: 1 under high stringency conditions.